Mr. Michal Efraty reports

NEUROTHERA LABS ANNOUNCES ADOPTION OF SEMI-ANNUAL REPORTING

Neurothera Labs Inc. has adopted a semi-annual financial reporting framework, effective immediately. This change is being made pursuant to the Coordinated Blanket Order 51-933 (Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers).

CBO 51-933 allows eligible venture issuers to voluntarily move from a quarterly to a semi-annual financial reporting framework.

Transition details

Neurothera's fiscal year ends on Dec. 31. Under the SAR framework, the company will be exempt from filing interim financial reports and related management's discussion and analysis for its first and third quarters for so long as it continues to meet eligibility criteria under CBO 51-933.

By adopting the SAR, Neurothera aims to reduce the administrative and financial burden associated with quarterly reporting, allowing management to focus resources on advancement of different projects.

• Initial interim period: The company will not file an interim report for the first quarter ended March 31, 2026, and for the third quarter ending Sept. 30, 2026.
• Continuing reporting: Neurothera will continue to file audited annual consolidated financial statements (due within 120 days of Dec. 31, 2026) and six-month interim financial reports (due within 60 days of June 30).
• Continued disclosure: The company remains committed to timely disclosure and will continue to report all material changes and significant developments as required under National Instrument 51-102.
• Eligibility: Neurothera confirms it meets the pilot program's eligibility criteria, which include being a venture issuer with annual revenues of less than$10-million and maintaining a clean 12-month continuous disclosure record.
• Continued participation: Should the company cease to continue participating in the SAR pilot program, it will announce it in a future news release.

About Neurothera Labs Inc.

Neurothera is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.